Syndax Pharmaceuticals, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $8.76M, a 10448.19% increase year-over-year.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $7.46M, a 1837.66% increase year-over-year.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $5.31M.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $6.36M, a 148.07% increase year-over-year.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $12.14M, a 51.73% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $8.00M, a 56.01% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $5.13M, a 55.25% decline from fiscal 2022.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $11.46M, a 80.86% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $8.76M 10-Q · filed 2026-08-04 | $27.89M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $7.46M 10-Q · filed 2026-08-04 | $19.21M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $5.31M derived: 10-K 12 month − 3 quarters · filed 2026-02-26 | $12.14M 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.36M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $83.00K 10-Q · filed 2025-11-03 | |
| 2025-03-31 | $385.00K 10-Q · filed 2026-04-30 | |
| 2024-12-31 | $8.00M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $2.56M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $439.00K 10-Q · filed 2025-11-03 | |
| 2024-03-31 | $1.86M 10-Q · filed 2025-11-03 | |
| 2023-12-31 | $5.13M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $1.59M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $1.15M 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $2.28M 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $11.46M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $7.36M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $2.23M 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $465.00K 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $6.34M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $1.61M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $825.00K 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $881.00K 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $6.63M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $1.71M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $1.01M 10-Q · filed 2021-11-15 | |
| 2020-03-31 | $338.00K 10-Q · filed 2021-11-15 | |
| 2019-12-31 | $178.00K 10-K · filed 2022-03-01 | |
| 2019-09-30 | $27.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $151.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $26.00K 10-K · filed 2021-03-12 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | |
| 2018-06-30 | $26.00K 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $277.00K 10-K · filed 2020-03-05 |
| 2017-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | |
| 2016-12-31 | $206.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $2.06M 10-K · filed 2019-03-07 |
| 2015-12-31 | $75.00K 10-K · filed 2018-03-08 | |
| 2014-12-31 | $6.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |